Advertisement
RYTM vs VRCA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYTM is a StrongBuy and VRCA is a StrongBuy.
RYTM's RSI Indicator ascending out of oversold territory
The RSI Oscillator for RYTM moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In 15 of the 17 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 54 cases where RYTM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on RYTM as a result. In 62 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +4.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 237 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
RYTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for RYTM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (60.774) is slightly higher than the industry average of (2.973). P/E Ratio (-29.135) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
VRCA sees its Stochastic Oscillator ascending out of oversold territory
On October 22, 2026, the Stochastic Oscillator for VRCA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In 58 of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VRCA's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 223 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
VRCA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRCA as a result. In 81 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VRCA turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VRCA entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.276) is normal, around the industry mean (2.973). P/E Ratio (-2.201) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. VRCA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RYTM | VRCA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 22 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 83 | |
P/E GROWTH RATING 1..100 | 25 | 16 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRCA's Valuation (83) in the Pharmaceuticals Major industry is in the same range as RYTM (89) in the Biotechnology industry. This means that VRCA’s stock grew similarly to RYTM’s over the last 12 months.
RYTM's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew significantly faster than VRCA’s over the last 12 months.
RYTM's SMR Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew similarly to VRCA’s over the last 12 months.
RYTM's Price Growth Rating (62) in the Biotechnology industry is in the same range as VRCA (83) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew similarly to VRCA’s over the last 12 months.
VRCA's P/E Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as RYTM (25) in the Biotechnology industry. This means that VRCA’s stock grew similarly to RYTM’s over the last 12 months.
| RYTM | VRCA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Advances ODDS (%) | 4 days ago 81% | 1 day ago 86% |
| Declines ODDS (%) | 11 days ago 73% | 5 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RYTM’s FA Score shows that 2 FA rating(s) are green while VRCA’s FA Score has 1 green FA rating(s).
- RYTM’s FA Score: 2 green, 3 red.
- VRCA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RYTM’s TA Score shows that 6 TA indicator(s) are bullish while VRCA’s TA Score has 4 bullish TA indicator(s).
- RYTM’s TA Score: 6 bullish, 2 bearish.
- VRCA’s TA Score: 4 bullish, 4 bearish.
Price Growth
RYTM (@Biotechnology) experienced а +3.33% price change this week, while VRCA (@Biotechnology) price change was +1.32% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
RYTM is expected to report earnings on Nov 03, 2026.
VRCA is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RYTM and
Correlation & Price change
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.
| Ticker / NAME | Correlation To RYTM | 1D Price Change % | ||
|---|---|---|---|---|
| RYTM | 100% | +2.57% | ||
| SRRK - RYTM | 46% Loosely correlated | -2.42% | ||
| VIR - RYTM | 44% Loosely correlated | -1.32% | ||
| ACAD - RYTM | 41% Loosely correlated | +0.59% | ||
| BEAM - RYTM | 41% Loosely correlated | -1.13% | ||
| XNCR - RYTM | 40% Loosely correlated | +2.70% | ||
More | ||||
VRCA and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with SVRA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To VRCA | 1D Price Change % | ||
|---|---|---|---|---|
| VRCA | 100% | +5.51% | ||
| SVRA - VRCA | 37% Loosely correlated | -2.78% | ||
| SANA - VRCA | 36% Loosely correlated | +0.85% | ||
| RYTM - VRCA | 35% Loosely correlated | +2.57% | ||
| KTTA - VRCA | 34% Loosely correlated | -8.73% | ||
| PHVS - VRCA | 32% Poorly correlated | +0.07% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JHMU | 25.37 | 0.24 | +0.94% |
| John Hancock Dynamic Municipal Bond ETF (JHMU) | |||
| AGD | 11.28 | 0.02 | +0.18% |
| abrdn Global Dynamic Dividend Fund | |||
| UCIB | 37.96 | -0.40 | -1.04% |
| ETRACS CMCI Total Return ETN Series B (UCIB) | |||
| NVDY | 11.61 | -0.46 | -3.81% |
| YieldMax NVDA Option Income Strategy ETF (NVDY) | |||
| STLR | 20.07 | -1.10 | -5.18% |
| Stellar ETF | |||